210 related articles for article (PubMed ID: 37298909)
1. New Functions of Intracellular LOXL2: Modulation of RNA-Binding Proteins.
Eraso P; Mazón MJ; Jiménez V; Pizarro-García P; Cuevas EP; Majuelos-Melguizo J; Morillo-Bernal J; Cano A; Portillo F
Molecules; 2023 May; 28(11):. PubMed ID: 37298909
[TBL] [Abstract][Full Text] [Related]
2. Lysyl oxidase-like 2 is a regulator of angiogenesis through modulation of endothelial-to-mesenchymal transition.
de Jong OG; van der Waals LM; Kools FRW; Verhaar MC; van Balkom BWM
J Cell Physiol; 2019 Jul; 234(7):10260-10269. PubMed ID: 30387148
[TBL] [Abstract][Full Text] [Related]
3. LOXL2 in cancer: regulation, downstream effectors and novel roles.
Wen B; Xu LY; Li EM
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188435. PubMed ID: 32976981
[TBL] [Abstract][Full Text] [Related]
4. LOXL2 in epithelial cell plasticity and tumor progression.
Cano A; Santamaría PG; Moreno-Bueno G
Future Oncol; 2012 Sep; 8(9):1095-108. PubMed ID: 23030485
[TBL] [Abstract][Full Text] [Related]
5. MCF-7 cells expressing nuclear associated lysyl oxidase-like 2 (LOXL2) exhibit an epithelial-to-mesenchymal transition (EMT) phenotype and are highly invasive in vitro.
Moon HJ; Finney J; Xu L; Moore D; Welch DR; Mure M
J Biol Chem; 2013 Oct; 288(42):30000-30008. PubMed ID: 24014025
[TBL] [Abstract][Full Text] [Related]
6. Specific protein 1(SP1) regulates the epithelial-mesenchymal transition via lysyl oxidase-like 2(LOXL2) in pancreatic ductal adenocarcinoma.
Kim IK; Lee YS; Kim HS; Dong SM; Park JS; Yoon DS
Sci Rep; 2019 Apr; 9(1):5933. PubMed ID: 30976063
[TBL] [Abstract][Full Text] [Related]
7. Lysyl Oxidase-like Protein LOXL2 Promotes Lung Metastasis of Breast Cancer.
Salvador F; Martin A; López-Menéndez C; Moreno-Bueno G; Santos V; Vázquez-Naharro A; Santamaria PG; Morales S; Dubus PR; Muinelo-Romay L; López-López R; Tung JC; Weaver VM; Portillo F; Cano A
Cancer Res; 2017 Nov; 77(21):5846-5859. PubMed ID: 28720577
[TBL] [Abstract][Full Text] [Related]
8. LOXL2 drives epithelial-mesenchymal transition via activation of IRE1-XBP1 signalling pathway.
Cuevas EP; Eraso P; Mazón MJ; Santos V; Moreno-Bueno G; Cano A; Portillo F
Sci Rep; 2017 Mar; 7():44988. PubMed ID: 28332555
[TBL] [Abstract][Full Text] [Related]
9. Lysyl oxidase-like-2 (LOXL2) is a major isoform in chondrocytes and is critically required for differentiation.
Iftikhar M; Hurtado P; Bais MV; Wigner N; Stephens DN; Gerstenfeld LC; Trackman PC
J Biol Chem; 2011 Jan; 286(2):909-18. PubMed ID: 21071451
[TBL] [Abstract][Full Text] [Related]
10. Clinical Implications of Lysyl Oxidase-Like Protein 2 Expression in Pancreatic Cancer.
Tanaka N; Yamada S; Sonohara F; Suenaga M; Hayashi M; Takami H; Niwa Y; Hattori N; Iwata N; Kanda M; Tanaka C; Kobayashi D; Nakayama G; Koike M; Fujiwara M; Fujii T; Kodera Y
Sci Rep; 2018 Jun; 8(1):9846. PubMed ID: 29959362
[TBL] [Abstract][Full Text] [Related]
11. Silencing of lysyl oxidase‑like 2 inhibits the migration, invasion and epithelial‑to‑mesenchymal transition of renal cell carcinoma cells through the Src/FAK signaling pathway.
Hong X; Yu JJ
Int J Oncol; 2019 May; 54(5):1676-1690. PubMed ID: 30816490
[TBL] [Abstract][Full Text] [Related]
12. Reciprocal regulation of LOX and LOXL2 expression during cell adhesion and terminal differentiation in epidermal keratinocytes.
Fujimoto E; Tajima S
J Dermatol Sci; 2009 Aug; 55(2):91-8. PubMed ID: 19394199
[TBL] [Abstract][Full Text] [Related]
13. Multiple Roles of LOXL2 in the Progression of Hepatocellular Carcinoma and Its Potential for Therapeutic Targeting.
Radić J; Kožik B; Nikolić I; Kolarov-Bjelobrk I; Vasiljević T; Vranjković B; Despotović S
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511503
[TBL] [Abstract][Full Text] [Related]
14. Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma.
Alonso-Nocelo M; Ruiz-Cañas L; Sancho P; Görgülü K; Alcalá S; Pedrero C; Vallespinos M; López-Gil JC; Ochando M; García-García E; David Trabulo SM; Martinelli P; Sánchez-Tomero P; Sánchez-Palomo C; Gonzalez-Santamaría P; Yuste L; Wörmann SM; Kabacaoğlu D; Earl J; Martin A; Salvador F; Valle S; Martin-Hijano L; Carrato A; Erkan M; García-Bermejo L; Hermann PC; Algül H; Moreno-Bueno G; Heeschen C; Portillo F; Cano A; Sainz B
Gut; 2023 Feb; 72(2):345-359. PubMed ID: 35428659
[TBL] [Abstract][Full Text] [Related]
15. LOXL2 small molecule inhibitor restrains malignant transformation of cervical cancer cells by repressing
Peng T; Lin S; Meng Y; Gao P; Wu P; Zhi W; Ding W; Cao C; Wu P
Cell Cycle; 2022 Sep; 21(17):1827-1841. PubMed ID: 35509127
[TBL] [Abstract][Full Text] [Related]
16. Escin Ia suppresses the metastasis of triple-negative breast cancer by inhibiting epithelial-mesenchymal transition via down-regulating LOXL2 expression.
Wang Y; Xu X; Zhao P; Tong B; Wei Z; Dai Y
Oncotarget; 2016 Apr; 7(17):23684-99. PubMed ID: 27008697
[TBL] [Abstract][Full Text] [Related]
17. LOXL2 induces aberrant acinar morphogenesis via ErbB2 signaling.
Chang J; Nicolau MM; Cox TR; Wetterskog D; Martens JW; Barker HE; Erler JT
Breast Cancer Res; 2013; 15(4):R67. PubMed ID: 23971878
[TBL] [Abstract][Full Text] [Related]
18. LOXL2-mediated matrix remodeling in metastasis and mammary gland involution.
Barker HE; Chang J; Cox TR; Lang G; Bird D; Nicolau M; Evans HR; Gartland A; Erler JT
Cancer Res; 2011 Mar; 71(5):1561-72. PubMed ID: 21233336
[TBL] [Abstract][Full Text] [Related]
19. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment.
Wang M; Zhao X; Zhu D; Liu T; Liang X; Liu F; Zhang Y; Dong X; Sun B
J Exp Clin Cancer Res; 2017 Apr; 36(1):60. PubMed ID: 28449718
[TBL] [Abstract][Full Text] [Related]
20. Functional analysis of LOXL2 in pancreatic carcinoma.
Rückert F; Joensson P; Saeger HD; Grützmann R; Pilarsky C
Int J Colorectal Dis; 2010 Mar; 25(3):303-11. PubMed ID: 20012301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
